FDA Approves Immunotherapy for Cutaneous Squamous-cell Carcinoma
Adding immunotherapy to treatment improves outcomes for people with a high-risk form of this common skin cancer.
Progress Against Cancer
Adding immunotherapy to treatment improves outcomes for people with a high-risk form of this common skin cancer.
Daratumumab and hyaluronidase-fihj is now indicated as part of a combination therapy for the potentially fatal condition that can develop in patients with multiple myeloma. The U.S. Food and Drug Administration (FDA) has granted...
FDA expands selumetinib approval to include treatment of adults with inoperable plexiform neurofibromas. The U.S. Food and Drug Administration (FDA) has approved selumetinib (Koselugo) for adults with neurofibromatosis type 1 (NF1) who have symptomatic,...
The FDA approved pertuzumab-dpzb for interchangeable use with pertuzumab. The U.S. Food and Drug Administration (FDA) has approved pertuzumab-dpzb (Poherdy) as a biosimilar to pertuzumab (Perjeta) for certain adults with HER2-positive breast cancer. Pertuzumab-dpzb...
The FDA has approved the menin inhibitor ziftomenib for adults with relapsed or refractory acute myeloid leukemias harboring susceptible NPM1 mutations. The U.S. Food and Drug Administration (FDA) has approved the use of the...
The FDA approved daratumumab and hyaluronidase-fihj for adults with smoldering multiple myeloma that has a high risk of progression. The U.S. Food and Drug Administration (FDA) has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) as...
The FDA has approved the menin inhibitor revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation in certain adult and pediatric patients 1 year and older. The U.S. Food and...
The FDA approved the BCMA-targeted antibody-drug conjugate belantamab mafodotin-blmf as part of a combination therapy for adults with refractory or recurrent multiple myeloma. The U.S. Food and Drug Administration (FDA) has approved belantamab mafodotin-blmf...
The FDA approved cemiplimab-rwlc as an adjuvant therapy for patients with cutaneous squamous cell carcinoma at high risk of recurrence. The U.S. Food and Drug Administration (FDA) has approved cemiplimab-rwlc (Libtayo) for use after...
The FDA has approved the DNA-damaging agent in combination with immunotherapy for patients whose cancers have not progressed after first-line therapy. The U.S. Food and Drug Administration (FDA) has approved lurbinectedin (Zepzelca) in combination...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More